Bayer sues Johnson & Johnson over Erleada ads, seeks injunction and treble damages

Bayer filed a false‑advertising lawsuit against Johnson & Johnson and its Janssen Biotech unit on Feb. 23, 2026 in the U.S. District Court for the Southern District of New York, accusing J&J of running a promotional campaign that misrepresented the mortality advantage of its prostate‑cancer drug Erleada relative to Bayer’s Nubeqa (darolutamide). The complaint, docketed as 1:26‑cv‑01479 and assigned to Judge Dale E. Ho, seeks an immediate injunction, a court‑ordered corrective press release, disgorgement of profits, compensatory and treble punitive damages and costs.

Bayer’s filing focuses on a “real‑world head‑to‑head analysis” that J&J publicized in a Feb. 2 press release and two presentations on its Medical Connect site, which the complaint says touted superior overall survival at 24 months for patients treated with Erleada who were not given the chemotherapy docetaxel. Bayer describes the materials as “commercial speech” intended to boost Erleada’s market share and says the analysis is “a scientifically flawed real‑world evidence analysis that misinforms healthcare providers and patients in an effort to increase its market share in a concentrated and increasingly competitive prostate cancer treatment market.”

The suit presses Lanham Act claims for false and misleading commercial representations about a product’s safety and efficacy. Bayer also alleges in the complaint that J&J “By invoking FDA authority to lend unwarranted credibility to scientifically flawed analyses, J&J has misled patients and healthcare providers.” The complaint pleads at least $75,000 to satisfy federal jurisdictional requirements; the company says the ultimate damages will be determined through litigation.

Johnson & Johnson pushed back in a brief emailed statement, saying in part, “Litigation does not change data. Our analysis was designed to meet rigorous guidance on real‑world evidence, and this legal action demonstrates Bayer’s obvious misunderstanding of methodological frameworks and real‑world evidence principles.” The company has characterized Erleada as a multibillion‑dollar franchise and has promoted the head‑to‑head analysis as real‑world evidence supporting its product.

The filing puts a spotlight on two converging shifts in oncology markets: the rising commercial importance of real‑world evidence and intensifying competition among next‑generation prostate‑cancer drugs. FiercePharma and other trade outlets have noted that Nubeqa has emerged as a significant rival to Erleada, raising the commercial stakes for comparative claims. Bayer retained Simpson Thacher & Bartlett LLP, according to docket listings summarized by Law360.

If the court grants the injunctive relief Bayer seeks, J&J could be ordered to stop disseminating the disputed materials and to publish corrective messaging, a remedy that would carry reputational as well as financial effects. The case also threatens to set precedents on how companies may use observational real‑world analyses in promotional materials and whether invoking regulatory frameworks confers additional credibility in commercial disputes.

Short‑term market effects are likely to revolve around physician perception and prescribing choices, particularly while the parties litigate. Longer term, courts and regulators will have to reconcile commercial speech protections with the increasing use of nonrandomized evidence in drug marketing. The SDNY docket and J&J’s Feb. 2 press release and Medical Connect presentations will be key documents to watch as the litigation proceeds.